Abu Dhabi has opened a new shared laboratory space for biotechnology companies at Masdar City, aiming to position the UAE as a hub for life sciences innovation and attract international biotech firms seeking to establish a presence in the Gulf region.
The facility, called Biosphere Labs, was developed with healthcare group M42 and will be operated by Attentive Science. It provides specialist equipment to startups and overseas companies looking to establish operations in the UAE without the cost of building their own research facilities. According to AGBI reporting on July 15, 2026, the lab has capacity for up to 36 companies and will begin onboarding tenants at the end of July.
Tareq Abu-Nadi, chief executive of Attentive Science, said he expects that within three to five years, at least four or five novel ideas will emerge from companies in the facility, eventually acquired by large pharmaceutical companies or developed through to clinical trials. Abu-Nadi relocated from California after selling his contract drug development business.
Approximately one-third of the available space has already been verbally reserved, primarily by U.S. biotechnology companies seeking to expand into the Gulf. Attentive Science has invested about $1.5 million in laboratory equipment, while the total investment in preparing the facility exceeds $2 million.
The regulatory environment was a key factor in choosing Abu Dhabi. Abu-Nadi noted that submitting an investigational new drug application to the U.S. Food and Drug Administration can cost companies more than $1 million and typically takes three to four months for review. Abu Dhabi’s Department of Health reviews equivalent applications within 28 days and does not charge government review fees. “The regulatory environment made it an easy decision,” he said.
The facility aligns with Abu Dhabi’s broader Healthcare Life Science Vision and Strategy, launched by the Department of Health in 2023. The strategy aims to increase the sector’s economic activity by $32 billion, launch 290 biotech startups, increase active clinical trials to more than 600, establish at least 24 new life sciences manufacturing sites, and create 22,000 jobs.
Masdar City chief executive Ahmed Baghoum said the Biosphere Labs model will serve as a catalyst for attracting global talent, accelerating homegrown discoveries, and translating scientific breakthroughs into real-world solutions. The development comes alongside other UAE biotech initiatives, including Dubai’s plans for a new medical tourism visa and a broader push for homegrown pharmaceutical manufacturing.
For the UAE’s business community, Biosphere Labs represents a tangible step toward diversifying the economy beyond oil and hydrocarbons. The facility’s focus on attracting real companies developing genuine intellectual property, rather than simply serving as a branding exercise, signals a commitment to building a substantive biotech ecosystem. With its faster regulatory approvals and growing infrastructure, the UAE is positioning itself as a competitive alternative to traditional biotech hubs in the U.S. and Europe.
